8-K: ProMIS Neurosciences Launches $18M ATM Offering

ProMIS Neurosciences Inc. has established an At The Market offering program to sell up to $17.99 million in common shares through H.C. Wainwright & Co., LLC.

Summary

• ProMIS Neurosciences Inc. entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co, LLC on August 13, 2025.
• The agreement allows the company to offer and sell common shares with an aggregate offering price of up to $17,988,524.
• Sales will be conducted from time to time at the company's sole discretion through the agent, H.C. Wainwright & Co, LLC, via at-the-market offerings on The Nasdaq Capital Market or other existing trading markets.
• The company will pay the agent a commission of up to 3% of the gross sales proceeds of any shares sold.
• No sales will commence until the company's shelf Registration Statement on Form S-3 (File No. 333-289577), filed on August 13, 2025, is declared effective by the SEC.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. While it introduces potential future dilution, the establishment of an At The Market offering program provides the company with a flexible and efficient mechanism to raise capital as needed, which is crucial for a company in the neuroscience sector. It indicates proactive financial management to ensure liquidity for ongoing operations and development.

Positives

• Establishes a flexible and efficient mechanism for future capital raises, allowing the company to access funding as needed.
• Provides potential access to up to $17,988,524 in funding, which can support ongoing operations, research, and development.
• Allows the company to raise capital opportunistically based on market conditions, potentially minimizing immediate dilutive impact compared to a single large offering.

Negatives

• Potential for future share dilution as common shares are sold into the market, which could negatively impact existing shareholder value.
• The actual amount of capital raised is uncertain and depends on market conditions, the company's discretion, and the effectiveness of the registration statement.
• A commission of up to 3% of gross sales proceeds will reduce the net funds received by the company from the offering.

Risks

• Market price volatility of the common shares could significantly impact the total amount of capital that can be raised through the ATM program.
• Future sales under the ATM program could create downward pressure on the stock price due to an increased supply of shares in the market.
• The commencement of sales is contingent on the SEC declaring the Form S-3 Registration Statement effective, introducing a regulatory dependency.

Future Outlook

The company intends to use the At The Market offering program to raise capital opportunistically, with sales contingent upon the SEC declaring its Form S-3 Registration Statement effective. This program provides a flexible financing tool for future capital needs.

Management Comments

• The Agent will use commercially reasonable efforts to sell the Shares from time to time consistent with its normal sales practices and applicable federal rules, regulations and Nasdaq rules, based upon instructions from the Company.
• The Company will apply the Net Proceeds from the sale of the Shares in the manner set forth in the Prospectus.

Industry Context

This At The Market (ATM) offering is a common financing strategy for biotechnology and neuroscience companies, particularly those in development stages, to secure ongoing funding for research, clinical trials, and general corporate purposes. It allows for gradual capital infusion, adapting to market demand and project milestones, which is crucial for companies with long development cycles and significant capital requirements.

Comparison to Industry Standards

• The 'at the market' offering structure is a standard and widely used method for public companies, especially in the biotech sector, to raise capital flexibly without the need for a single, large, underwritten offering.
• The commission rate of up to 3% is within the typical range for ATM programs, which generally vary from 1% to 3% depending on the size of the offering, liquidity of the stock, and market conditions.
• The reliance on an effective S-3 registration statement is a standard regulatory prerequisite for such offerings in the U.S., ensuring compliance with SEC disclosure requirements.

Stakeholder Impact

• Shareholders: Potential for dilution from future share issuances, but also provides financial stability for company operations and strategic initiatives.
• Company: Enhanced financial flexibility and access to capital for strategic initiatives, research, and development.
• H.C. Wainwright & Co, LLC: Will earn commissions on shares sold through the ATM program.

Next Steps

• The SEC must declare the shelf Registration Statement on Form S-3 effective before any sales under the ATM program can commence.
• The company will issue and sell common shares from time to time at its sole discretion through the agent.
• The company will disclose the number of shares sold, net proceeds, and compensation paid in future Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Key Dates

Recommendation

The ATM offering provides financial flexibility and a pathway for future capital, which is positive for a development-stage company. However, it also signals potential future dilution for existing shareholders. The actual impact on share price will depend on the timing and volume of sales, as well as the company's underlying operational performance and news flow. Investors should hold and monitor the execution of the ATM program and the company's progress in its core business.

Keywords

PROMIS Neurosciences, PMN, At The Market Offering, ATM, Equity Financing, Capital Raise, SEC Filing, Form S-3, Nasdaq, Biotechnology, Neuroscience